Supernus Pharmaceuticals Inc (SUPN)

Debt-to-capital ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	—	—	379,252	361,751	345,170
Total stockholders’ equity	US$ in thousands	1	0	815,851	744,858	595,428
Debt-to-capital ratio		0.00	—	0.32	0.33	0.37

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $1K)
= 0.00

The debt-to-capital ratio of Supernus Pharmaceuticals Inc has shown a decreasing trend over the past five years, indicating a lower reliance on debt financing relative to its total capital structure. In 2023, the company's debt-to-capital ratio decreased significantly to 0.00, reflecting a debt-free capital structure for that year. This could suggest that the company either paid off its debt obligations or utilized other financing sources.

Compared to the previous years, where the debt-to-capital ratio was 0.31 in 2022, 0.32 in 2021, 0.34 in 2020, and 0.37 in 2019, the decreasing trend indicates a potential improved financial health and reduced financial risk for Supernus Pharmaceuticals Inc. A lower debt-to-capital ratio signifies a lower proportion of debt in the company's capital structure and may indicate a stronger ability to meet financial obligations and withstand economic downturns.

However, while a decreasing trend in the debt-to-capital ratio is generally positive, it is essential to consider the reasons behind this reduction and assess the overall financial health and performance of the company comprehensively. Additional analysis of the company's financial statements, profitability, liquidity, and cash flow positions would provide a more holistic view of Supernus Pharmaceuticals Inc's financial stability and operational efficiency.